Cargando…

A semiquantitative study of the optimal whole-body imaging time after (131)I therapy for differentiated thyroid cancer

OBJECTIVE: We compared the efficacy of post-therapy whole-body scintigraphy (Tx-WBS) in terms of detecting lesions in patients with differentiated thyroid cancer (DTC) on days 3, 7, and 10 after (131)I treatment, and we determined the optimal imaging time. METHODS: Clinical data from 161 DTC patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shuang, Zuo, Rui, Yang, Tianyu, Pang, Hua, Wang, Zhengjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453647/ https://www.ncbi.nlm.nih.gov/pubmed/36093082 http://dx.doi.org/10.3389/fendo.2022.955387

Ejemplares similares

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
por: van der Boom, Trynke, et al.
Publicado: (2021)

Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated (131)I therapy?
por: Jiang, Yongji, et al.
Publicado: (2023)

Radioactive Body Burden Measurements in (131)Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body (131)Iodine Clearance
por: Ravichandran, Ramamoorthy, et al.
Publicado: (2014)

Cervical lymph node metastasis prediction of postoperative papillary thyroid carcinoma before (131)I therapy based on clinical and ultrasound characteristics
por: Yu, Fei, et al.
Publicado: (2023)

Prognostic Impact of Direct (131)I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study
por: Carrillo, José F., et al.
Publicado: (2019)

Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer
por: Iwano, Shingo, et al.
Publicado: (2020)

Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of (131)I Therapy in Patients With Differentiated Thyroid Cancer Following Total Thyroidectomy: A Retrospective Study
por: Pan, Mengjiao, et al.
Publicado: (2022)

Head-to-Head Comparison of (68)Ga-PSMA-11 and (131)I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent
por: Pitalua-Cortes, Quetzali, et al.
Publicado: (2021)

Semiquantitative assessment of (99m)Tc-MIBI uptake in parathyroids of secondary hyperparathyroidism patients with chronic renal failure
por: Yu, Dafu, et al.
Publicado: (2022)

Analysis of factors influencing the clinical outcome after surgery and (131)I therapy in patients with moderate-risk thyroid papillary carcinoma
por: Li, Yixuan, et al.
Publicado: (2022)

Clinical application of (18)F-FCH PET/CT in the diagnosis and treatment of hyperparathyroidism
por: Liu, Shuang, et al.
Publicado: (2023)

Outcome of Patients With Differentiated Thyroid Cancer Treated With 131-Iodine on the Basis of a Detectable Serum Thyroglobulin Level After Initial Treatment
por: Klain, Michele, et al.
Publicado: (2019)

Inguinal Endometriosis Visualized on I-131 Whole Body Scan
por: Çayır, Derya, et al.
Publicado: (2018)

A Quantitative Evaluation of Hepatic Uptake on I-131 Whole-Body Scintigraphy for Postablative Therapy of Thyroid Carcinoma
por: Nakayama, Michihiro, et al.
Publicado: (2015)

Stunning in post (131)I therapy scans after low-dose (131)I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: Critical importance of interval between the two scans
por: Damle, Nishikant A., et al.
Publicado: (2012)

Exophytic pancreatic lymphoepithelial cyst incidentally detected in a differentiated thyroid cancer patient on whole-body I-131 scan: a case report
por: Murokawa, Takahiro, et al.
Publicado: (2022)

Effect of (131)I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
por: Rui, Zhongying, et al.
Publicado: (2021)

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

In Thyroidectomized Thyroid Cancer Patients, False-Positive I-131 Whole Body Scans Are Often Caused by Inflammation Rather Than Thyroid Cancer
por: Garger, Yana Basis, et al.
Publicado: (2016)

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
por: Probst, Stephan, et al.
Publicado: (2018)

The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of (131)I Treatment in DTC Patients
por: Zheng, Wei, et al.
Publicado: (2021)

Pitfall of I-131 whole body scan: a mucinous adenocarcinoma of the ovary
por: Sellem, Ali, et al.
Publicado: (2020)

Clinical Value of (99m)Tc-3PRGD2 SPECT/CT in Differentiated Thyroid Carcinoma with Negative (131)I Whole-Body Scan and Elevated Thyroglobulin Level
por: Gao, Rui, et al.
Publicado: (2018)

Optimal administration time of vitamin C after (131)I therapy in differentiated thyroid cancer based on propensity score matching
por: Liu, Ye, et al.
Publicado: (2022)

Value of (18)F-FDG Hybrid PET/MR in Differentiated Thyroid Cancer Patients with Negative (131)I Whole-Body Scan and Elevated Thyroglobulin Levels
por: Li, Hongyan, et al.
Publicado: (2021)

Impact of (18)F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative (131)I whole body scan and elevated serum thyroglobulin
por: Boktor, Raef R., et al.
Publicado: (2022)

Values of (99m)Tc-methoxyisobutylisonitrile imaging after first-time large-dose (131)I therapy in treating differentiated thyroid cancer
por: Pan, Xiaomei, et al.
Publicado: (2016)

Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Oral, Aylin, et al.
Publicado: (2018)

Analysis of the incidence and influencing factors of hyponatremia before (131)I treatment of differentiated thyroid carcinoma
por: Cao, Jing-Jia, et al.
Publicado: (2021)

Effect of (131)I ‘clear residual thyroid tissue’ after surgery on the function of parathyroid gland in differentiated thyroid cancer
por: ZHAO, ZHI-HUA, et al.
Publicado: (2015)

The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
por: Zhang, Haiying, et al.
Publicado: (2014)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Unusual Sites of Metastatic and Benign I 131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Palaniswamy, Shanmuga S., et al.
Publicado: (2018)

MON-559 Inappropriate Dosing of I-131 in Non-Metastatic Differentiated Thyroid Cancer
por: Alzenaidi, Ahlam, et al.
Publicado: (2019)

Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for (131)I Administration
por: Gomes-Lima, Cristiane J, et al.
Publicado: (2022)

I-131 Avid Tumor Thrombus in a Case of Poorly Differentiated Thyroid Cancer
por: Gill, Sana Munir, et al.
Publicado: (2023)

Usefulness of second (131)I treatment in biochemical persistent differentiated thyroid cancer patients
por: Gambale, Carla, et al.
Publicado: (2023)

Utility of single photon emission computed tomography/CT hybrid imaging over planar I-131 whole body scans in detection of adrenal metastases in differentiated thyroid cancer
por: Damle, Nishikant, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pebkcimrm6q0jja32ritia1l8f